Navigation Links
US Oncology Named to FORTUNE Magazine's World's Most Admired Companies List for Fifth Time
Date:3/5/2010

THE WOODLANDS, Texas, March 5 /PRNewswire/ -- US Oncology, Inc., the leading oncology services company uniting the nation's largest cancer treatment and research network to expand patient access to high-quality, cost-effective cancer care and advance the science of cancer care, has been named to FORTUNE magazine's World's Most Admired Companies list for 2010. The company ranks second in the Health Care: Pharmacy and Other category, up from third place in 2009. This is the fifth time US Oncology has been honored with FORTUNE magazine's World's Most Admired Companies distinction, having been named to the list in 2003, 2004, 2007, and 2009.

The magazine's annual list is considered the definitive report card on corporate reputations. Ranked by top industry executives and financial analysts on nine areas of leadership, US Oncology placed first in the categories of People Management and Social Responsibility, and second in its sector in the categories of Innovation, Use of Corporate Assets, and Quality of Management. The company ranks in the top five of eight categories, including Long-Term Investment (ranked 3), Quality of Product Services and Global Competitiveness (ranked 5).

US Oncology uses its expertise, insight and passion for eradicating cancer to develop innovative solutions that advance the quality and cost-effectiveness of cancer care. Through the use of technology, research, world-class evidence-based pathways, and patient education and support, the company works with physicians, patients, payers and the medical industry to improve patients' lives and advance the science and value of cancer care; and enables physicians to deliver this high quality care in the communities where patients live.

About US Oncology

US Oncology, Inc. is the leading oncology services company uniting the nation's largest cancer treatment and research network to expand patient access to high-quality, cost-effective cancer care and advance the science of cancer care. Headquartered in The Woodlands, Texas, US Oncology provides a broad range of solutions to community oncologists, patients, payers, and the medical industry across all phases of the cancer care research and delivery system, and deploys innovation, technology, research and the use of evidence-based medicine and shared best practices to improve patient outcomes and offer a better patient experience. For more information, visit www.usoncology.com.

SOURCE US Oncology, Inc.

Back to top

RELATED LINKS
http://www.usoncology.com

'/>"/>

SOURCE US Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone
2. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
3. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
4. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
5. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
6. US Oncology Announces Retirement of General Counsel Phil Watts
7. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
8. Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
9. MedTrust Online Surpasses 5,000 Registered Users and Adds Dr. Henry Friedman to Oncology Advisory Board
10. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
11. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... a United States multicenter, prospective clinical study that demonstrates the accuracy of ... capable of identifying clinically significant acute bacterial and viral respiratory tract infections ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality ... Several trends in analytical testing are being attributed to new regulatory requirements for ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board ... Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced ... for membership in ARCS Alumni Hall of Fame . ASTER Labs is ...
(Date:10/11/2017)... ... ... eye wash is a basic first aid supply for any work environment, but most personal ... rinse first if a dangerous substance enters both eyes? It’s one less decision, and likely ... dual eye piece. , “Whether its dirt and debris, or an acid or alkali, getting ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
Breaking Biology News(10 mins):